Arbutus Biopharma Corporation
ABUS
$4.46
-$0.44-8.98%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.42M | 6.40M | 6.17M | 6.74M | 10.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.42M | 6.40M | 6.17M | 6.74M | 10.06M |
| Cost of Revenue | 32.42M | 33.16M | 39.61M | 48.36M | 54.26M |
| Gross Profit | -17.00M | -26.76M | -33.43M | -41.62M | -44.19M |
| SG&A Expenses | 22.13M | 26.35M | 25.83M | 22.50M | 23.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.67M | 73.94M | 79.87M | 85.29M | 92.49M |
| Operating Income | -44.25M | -67.54M | -73.69M | -78.55M | -82.43M |
| Income Before Tax | -54.25M | -76.57M | -69.92M | -76.70M | -77.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.25 | -76.57 | -69.92 | -76.70 | -77.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.25M | -76.57M | -69.92M | -76.70M | -77.09M |
| EBIT | -44.25M | -67.54M | -73.69M | -78.55M | -82.43M |
| EBITDA | -43.24M | -66.18M | -72.31M | -77.14M | -80.99M |
| EPS Basic | -0.29 | -0.40 | -0.38 | -0.43 | -0.44 |
| Normalized Basic EPS | -0.13 | -0.20 | -0.23 | -0.25 | -0.27 |
| EPS Diluted | -0.29 | -0.41 | -0.39 | -0.43 | -0.45 |
| Normalized Diluted EPS | -0.13 | -0.20 | -0.23 | -0.25 | -0.27 |
| Average Basic Shares Outstanding | 760.96M | 757.45M | 742.37M | 721.25M | 699.77M |
| Average Diluted Shares Outstanding | 761.81M | 757.45M | 742.37M | 721.25M | 699.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |